PTGER2
ENSG00000125384
Target class
GPCR
Chromosome
14
Approved drugs
3
Clinical candidates (approved and in development)
7
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- Yes
- Target name
- PTGER2
- Gene name
- Prostaglandin E receptor 2
- Gene symbol
- PTGER2
- Protein name
- Prostaglandin E2 receptor EP2 subtype (PGE receptor EP2 subtype) (PGE2 receptor EP2 subtype) (Prostanoid EP2 receptor)
- EP2
- COX-2
- Gene biotype
- Protein coding
- Gene family
- Prostaglandin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 35
- Highest tissue expression
- 54.87
- Tissue specificity (Gini)
- 0.68
- Tissue specificity (tau)
- 0.909
- KEGG gene identifiers
- hsa:5732
- Protein interaction confidence
- 0.853286
- Protein interaction partners
- 21
- R-HSA-391908
- R-HSA-418555
- End position
- 52329822
- Start position
- 52314305
- Chromosome
- 14
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.908786
- Expression inequality (Gini)
- 0.680209
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 54.87
- Cervix - Endocervix
- 34.01
- Whole Blood
- 24.65
- Spleen
- 19.73
- Cervix - Ectocervix
- 18.88
Expression in transcripts per million
- Cells - Cultured fibroblasts54.87
- Cervix - Endocervix34.01
- Whole Blood24.65
- Spleen19.73
- Cervix - Ectocervix18.88
- Uterus15.41
- Prostate13.59
- Small Intestine - Terminal Ileum12.88
- Ovary11.91
- Adipose - Visceral (Omentum)10.83
- Lung10.46
- Stomach9.78
- Adipose - Subcutaneous7.19
- Colon - Transverse6.86
- Fallopian Tube5.34
- Nerve - Tibial5.33
- Kidney - Medulla5.18
- Breast - Mammary Tissue4.9
- Bladder4.33
- Esophagus - Gastroesophageal Junction4.06
- Minor Salivary Gland3.94
- Thyroid3.6
- Testis3.58
- Vagina3.51
- Esophagus - Muscularis3.16
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007189
Cellular components
- GO:0005886
Molecular functions
- GO:0004957
increased/decreased inflammation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased inflammation
- urogenital
- immune
PubMed 28216264decreased uterine motility
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased uterine motility
- urogenital
- immune
PubMed 28216264decreased/increased inflammation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased/increased inflammation
- urogenital
- immune
PubMed 28216264
regulation of gene expression
Studies
- cell-based: BSK_LPS_PGE2, is one of 11 assay component(s) measured or calculated from the BSK_LPS assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.
Biological samples
- umbilical vein endothelium and peripheral blood mononuclear cells, primary cell co-culture
Evidence source
Related records
Trials (749)
- 24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E
- 24-Hour Vaginal Dinoprostone Pessary Versus Gel for Labour Induction
- 400mcg Sublingual Misoprostol as First Line Treatment
- A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
- A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects
- A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects
- A Comparative Study Between Rectal and Intrauterine Misoprostol Administration in the Reduction of Blood Loss During and After Elective Cesarean Delivery in Low Risk Women
- A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor
- A Comparison of Sublingual and Buccal Misoprostol Regimens After Mifepristone for Mid-trimester Abortion
- A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study
- A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601
- A Novel Protocol for Labour Induction
- A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
- A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
- A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
- A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
- A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
Drugs (18)
- Alprostadil Prostanoid EP2 receptor agonist
- Dinoprost
- Dinoprostone Prostaglandin E2 receptor agonist
- Evatanepag Prostanoid EP2 receptor agonist
- Evatanepag sodium Prostanoid EP2 receptor agonist
- Iloprost
- Laselipag
- Misoprostol
- Misoprostol acid
- Omidenepag Prostanoid EP2 receptor agonist
- Omidenepag isopropyl Prostanoid EP2 receptor agonist
- PF-04418948
- Rioprostil
- Selexipag
- Simenepag isopropyl Prostanoid EP2 receptor agonist
- Taprenepag
- Taprenepag isopropyl Prostanoid EP2 receptor agonist
- Treprostinil